Tralokinumab Shows Strong Real-World Efficacy in Atopic Dermatitis for Patients With Skin of Color: April Armstrong, MD, MPH

Why It Matters

The findings demonstrate that tralokinumab is an effective, equitable treatment option for under‑represented patients with atopic dermatitis, addressing a long‑standing evidence gap.

Key Takeaways

• 80% of skin-of-color patients responded at 12 months
• TRACE enrolled >800 AD patients, 16% skin-of-color
• Efficacy matched overall population, showing consistent benefit
• Early improvements observed soon after treatment start
• Itch, quality of life, and sleep scores improved

Pulse Analysis

Real‑world evidence is reshaping dermatology, especially for conditions like atopic dermatitis (AD) that disproportionately affect patients of color. Historically, clinical trials have under‑sampled Fitzpatrick skin types 4‑6, leaving clinicians with limited data on how biologics perform in richly pigmented skin. The TRACE study bridges this gap by observing tralokinumab outcomes in a global, routine‑care setting, providing insights that randomized trials often cannot capture, such as adherence patterns and everyday quality‑of‑life impacts.

TRACE enrolled more than 800 adults initiating tralokinumab, with 16% identified as skin‑of‑color participants. Over a 12‑month follow‑up, 80% of these patients met the response criteria—either achieving clear or almost clear skin or reducing their Eczema Area and Severity Index (EASI) below 7. Notably, the speed of improvement was rapid, with measurable gains appearing shortly after the first dose. These efficacy metrics mirrored those observed in the broader study population, suggesting that the drug’s mechanism of targeting interleukin‑13 operates consistently regardless of melanin density or phenotypic variations.

For clinicians, the data translate into a stronger therapeutic rationale for prescribing tralokinumab to diverse AD patients, reinforcing confidence that skin‑of‑color individuals will experience comparable relief in itch, sleep disruption, and overall quality of life. Payers and formulary committees can also leverage these results to justify coverage decisions that promote equitable access. Looking ahead, the study underscores the need for more inclusive research designs, encouraging sponsors to embed diverse cohorts early in development pipelines, ultimately fostering a more representative evidence base for dermatologic care.